Abstract
Steroidal 5α-reductase is a system of NADPH dependent enzyme that catalyzes the irreversible conversion of Δ4–3-ketosteroid precursor (testosterone) to its corresponding 5α-reduced metabolite (dihydrotestosterone). Initial role of DHT was discovered through males pseudohermaphroditism, a genetic disorder with complete or partial 5α-reductase deficiency accompanied with features at critical juncture of fetal and postnatal development. However, excessive DHT production, has brought a revolution in revealing the etiology of complications like prostate cancer and benign prostatic hyperplasia. Over the last two decades, converging lines of evidences have highlighted the role of 5α-reductase inhibitors in the treatment of these androgen dependent disorders. Finasteride and Dutasteride, are the two clinically approved inhibitors available in the market, that helps in reducing the prostate volume by blocking the 5a-reductase enzyme.
Reference97 articles.
1. Kenny, B.; Ballard, S.; Blagg, J.; Fox, D.Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia. J. Med. Chem.1997, 40, 1293-1315
2. Arora RP, Nayak RL, Malhotra V, Mohanty NK, Kulkarni SK. Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia. Med Update2003;11:55-58
3. Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003; 361: 1359-1367
4. Djavan B, Remzi M, Erne B, Marberger M. The pathophysiology of benign prostatic hyperplasia. Drugs Today2002; 38: 867-870
5. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate1996; 28: 392-405
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献